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Acute Hemodynamic Effects of Norepinephrine Inhibition in Patients 
With Severe Chronic Congestive Heart Failure 
JOSEPH A. FRANCIOSA, MD, FACC, DAVID E. SCHWARTZ, MD* 
Philadelphia, Pennsylvania 
The pathophysiologic role of high levels of circulating 
catecholamines in patients with congestive heart failure 
remains unclear. To assess the hemodynamic contribution 
of circulating catecholamines, metyrosine (alpha-methyl- 
p-tyrosine), an inhibitor of catecholamine synthesis, was 
administered to nine patients with acutely decompensated 
chronic congestive heart failure. Baseline left ventricular 
ejection fraction averaged 23.3 * 9.91, whereas cardiac 
output averaged 3.69 + 1.03 literslmin, with a pulmonary 
wedge pressure of 27.4 f 8.5 mm Hg. 
After 48 h of metyrosine administration, plasma norep- 
inephrine concentration decreased from 919.4 + 810.6 to 
Neurohumoral abnormalities are known features of conges- 
tive heart failure. The successful therapeutic application of 
angiotensin-converting enzyme inhibitors clearly indicates 
that excessive renin-angiotensin activity contributes to the 
manifestations of heart failure. In contrast, the role of 
circulating catecholamines in similar patients remains un- 
clear. Observations that adrenergic inhibition may lessen 
symptoms in selected patients with heart failure and that 
there is a direct relation between catecholamine levels and 
mortality in patients with heart failure suggest that increased 
sympathetic nervous activity may be harmful in this setting 
(l-3). However, it has been suggested (4) that heightened 
sympathetic tone represents a desirable compensatory re- 
sponse to the failing heart and that withdrawal of this 
support could be harmful. In fact, sympathomimetic agents 
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335.4 k 143.1 pg/ml (p < 0.05). Plasma epinephrine 
concentration averaged 176.4 2 166.0 pg/ml at baseline, 
and was unchanged during metyrosine administration. 
Despite the significant decrease in circulating norepineph- 
rine, no significant hemodynamic changes were observed 
during metyrosine administration. 
These results suggest that high levels of circulating 
norepinephrine may be more a marker of severe congestive 
heart failure than an important contributor to the under- 
lying pathophysiology at this advanced stage of the disease 
process. 
(.I Am Co11 Cardiol1989;14:624-30) 
are commonly administered as effective treatment for acute 
severe heart failure. 
Thus, increased circulating catecholamines may play a 
significant role in the pathophysiology of established conges- 
tive heart failure or they may represent a mere marker of 
advanced heart disease. If catecholamines do play an impor- 
tant role, they may be harmful through increasing afterload 
and metabolic demands on the failing heart or they may be 
beneficial by helping to maintain blood pressure and cardiac 
output. Correlations between circulating catecholamine lev- 
els and hemodynamics have been poor in patients with heart 
failure (5). Therapeutic interventions aimed at increasing or 
inhibiting adrenergic tone have not yielded consistent re- 
sults, probably reflecting heterogeneity of patient study 
groups and associated pharmacologic actions of the agents 
employed (l,2,6-8). 
The present study was designed to assess the contribution 
of increased circulating catecholamines to the hemodynamic 
abnormalities observed in patients with heart failure. The 
study group chosen was one with acutely decompensated 
severe chronic congestive heart failure because such pa- 
tients are commonly treated with sympathomimetic agents 
and have high afterload. Thus, reduction of catecholamine 
levels might reasonably be expected to produce unequivocal 
hemodynamic improvement or worsening in these patients. 
The agent chosen to reduce catecholamine activity was 
metyrosine (alpha-methyl-p-tyrosine), whose only pharma- 
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cologic action is thought to be inhibition of catecholamine 
synthesis, especially that of norepinephrine (9,lO). 
Methods 
Patient selection. The study group consisted of nine men 
with acutely decompensated chronic congestive heart failure 
requiring hospitalization. For inclusion in the study. patients 
had to be between 18 and 70 years of age and have a history 
of chronic congestive heart failure due to coronary artery 
disease or idiopathic dilated cardiomyopathy. Congestive 
heart failure was defined as a history of exercise intolerance 
resulting from dyspnea or fatigue only, plus at least one of 
the following measurements obtained within the preceding 
30 days: left ventricular ejection fraction ~40% by contrast 
or radionuclide ventriculography, cardiothoracic ratio ~54% 
by standard chest X-ray study and left ventricular end- 
diastolic diameter >55 mm by M-mode echocardiography. 
Patients must have been experiencing increased symptoms 
or physical findings attributable to congestive heart failure 
despite treatment with at least digitalis and diuretic drugs 
during the preceding month. 
The diagnosis of coronary artery disease was established 
by a history of documented previous acute myocardial 
infarction (serial electrocardiographic [ECG] and serum en- 
zyme changes) or by angiographically proved coronary 
artery obstructive disease. Idiopathic dilated cardiomyopa- 
thy was diagnosed when no other cause of heart failure was 
apparent. Patients were excluded for any of the following 
conditions: acute myocardial infarction within the previous 3 
months, primary valvular heart disease, primary pulmonary 
disease, hypertension requiring treatment and inability to 
tolerate withdrawal of vasodilator therapy. 
Study protocol. Patients meeting these selection criteria 
gave written informed consent. The protocol was approved 
by the Human Studies Subcommittee of the local institu- 
tional review board. Vasodilator therapy was discontinued 
for at least 48 h before study, and digitalis and diuretic drugs 
were continued at constant doses throughout the study 
period. On the day of study, patients were brought to a 
special procedure room adjacent to the coronary care unit. A 
Swan-Ganz catheter was inserted percutaneously through a 
femoral or antecubital vein to record pulmonary artery and 
right atria1 pressures and measure cardiac output by ther- 
modilution. An intraarterial cannula was inserted into the 
brachial artery to measure intraarterial pressure. After all 
catheters were inserted, baseline hemodynamic measure- 
ments, including pulmonary artery occluded and phasic 
pressures, right atria1 pressure, systemic arterial pressure, 
heart rate (from continuous ECG monitoring) and cardiac 
output in triplicate, were obtained. Pulmonary wedge pres- 
sure was taken as pulmonary artery diastolic or occluded 
pressure, and these variables were not interchanged in any 
given patient. Control hemodynamic measurements were 
repeated at 20 min intervals until they were stable. Stability 
was defined as I 10% variation in any hemodynamic variable 
on two consecutive sets of measurements. 
On completion of baseline hemodynamic measurements, 
samples of mixed venous blood were obtained for measure- 
ment of plasma catecholamines by high performance liquid 
chromatography (11). Plasma renin activity was measured at 
baseline study by radioenzymatic assay as part of the 
assessment of patient characteristics. Metyrosine adminis- 
tration was then begun and repeated every 8 h for 48 h. 
Hemodynamic measurements were repeated at 4, 8, 24 and 
48 h after administration of the first dose of metyrosine. 
Mixed venous samples for plasma catecholamines were 
repeated at 24, 48 and 72 h after administration of the first 
dose of metyrosine. 
Metyrosine dose titration. Because of the lack of previous 
experience with metyrosine and the risks of catecholamine 
withdrawal in patients with severe heart failure, the initial 
dose of metyrosine in the first two patients was 250 mg every 
8 h. The dose was increased by 750 mg/day (in three divided 
doses) in successive pairs of patients until plasma norepi- 
nephrine was reduced 270% from control values in both 
members of the pair any time within the first 72 h after drug 
administration. In any case, the maximal allowable dose of 
metyrosine was I.500 mg every 8 h. This dosing regimen was 
chosen on the basis of previous experience with metyrosine 
in patients with pheochromocytoma (9,lO). The dose could 
not be increased in subsequent patients if undesirable symp- 
toms or side effects occurred in any patient. Similarly, any 
striking hemodynamic change judged to be potentially harm- 
ful, with or without symptoms, precluded an increase in 
dose. 
Data analysis. Because serial observations were made, 
all data were subjected to an analysis of variance, and paired 
t tests were made only if the F value was significant. 
Coefficients of correlation were obtained by standard linear 
regression analysis. A probability (p) value co.05 was con- 
sidered statistically significant for the paired t tests. When 
the Bonferroni correction was applied to the interpretation 
of coefficients of correlation (r), a p value <0.0015 was 
required for an r value to be considered statistically 
significant. 
Results 
Patient characteristics (Table I). In the study group of 
nine men. heart failure was caused by idiopathic dilated 
cardiomyopathy in six and coronary artery disease in the 
other three. By protocol, all patients had symptoms for 23 
months. with worsening during the preceding month ulti- 
mately requiring hospitalization. Symptomatic status was 
categorized as class III-IV (New York Heart Association 
criteria) in all patients despite treatment with at least digoxin 
and furosemide. In addition, three patients were taking other 
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Table 1. Characteristics of Nine Patients With Congestive Heart Failure Given Metyrosine 
Patient Age (yr) BSA NYHA LVEF CTR LVDD 
No. & Gender (m*) Dx Class @i) W (mml Prior Medications for CHF 
1 53M 1.86 IDC IV - 57 65 Dlgoxm, furosemide, hydralazine 
2 63M 1.73 CAD IV - 55 - Digoxin, furosemide, spironolactone, hydralazine, 
isosorbide din&ate 
3 SOM l.% IDC IV 44 60 Digoxin, furosemide, nitroglycerin 
4 65M 2.08 IDC III 21 59 50 Dlgoxin, furosemlde, hydrochlorothiazide, triamterene 
5 62M 1.84 IDC 111 13 60 73 Digoxin, furosemide 
6 53M 1.82 IDC 111 2s 53 63 Digoxin, furosemide, hydralazine. isosorbide dinitrate 
7 64M 1.76 CAD III 35 58 65 Digoxin, furosemide 
8 66M 1.62 CAD IV IO 46 62 Digoxin, furosemide, nitroglycerin 
Y 64M I .63 IDC 111 36 - - Ulgoxin, furosemide, hydrochlorothiazide, triamterene 
Mean 60.0 1.81 23.3 54.0 62.6 
+ SD 5.8 0.14 9.9 5.6 6.4 
BSA = body surface area; CAD = coronary artery disease; CHF = congestive heart fadure; CTR = cardiothoracic ratio; Dx = diagnosis; IDC = idiopathic 
dilated cardiomvoDathv: LVDD = left ventricular diastolic dimension: LVEF = left ventricular ejection fraction: NYHA Class = New York Heart Association 
functional class; SD =’ standard deviation. 
diuretic drugs, and five were receiving vasodilator therapy. 
All patients had cardiomegaly with increased cardiothoracic 
ratio or left ventricular end-diastolic dimension, and left 
ventricular ejection fraction was depressed in all six patients 
in whom it was measured. Thus, on the basis of symptoms, 
cardiac size and cardiac function, all patients had severe 
congestive heart failure at the time of study. 
Metyrosine dose (Table 2). The first dose that produced 
the desired responses in both members of the pair was 3,750 
mg (I ,250 mg three times a day), which lowered norepineph- 
rine levels by ~70% in both patients. For safety reasons 
relating to our lack of previous experience with metyrosine, 
the initial dose was given to both members of the first 
pair of patients even though the first patient did not meet 
the response criteria. Because the first patient in the 
third pair (Patient 5) did not meet the response criteria, a 
second patient did not receive that same dose (750 mg 
Table 2. Dose Titration of Metyrosine 
Metyrosine Maximal 
Patient Total Daily % Change in 
No. Dose (mg)* Norepinephrine 
I 750 -40 
2 750 -66 
3 1,500 -76 
4 1,500 -41 
5 2,250 -41 
6 3,ooo -82 
7 3.cW -40 
8 3.750 -86 
Y 3,750 -72 
*Administered in divided doses three times daily. 
three times a day). In all other pairs, the first patient 
met the response criteria, and the second patient was 
given the same dose of metyrosine. No patient experienced 
undesirable symptoms, side effects or hemodynamic re- 
sponses. 
Changes in plasma catecholamines during the 72 h after 
administration of metyrosine (Table 3). Norepinephrine lev- 
els were reduced at 24 h, with the peak significant reduction 
occurring by 48 h. Circulating epinephrine levels were not 
significantly altered by metyrosine. The baseline values for 
norepinephrine were generally high, averaging 919.4 * 810.6 
pgiml, consistent with advanced heart failure. Normal values 
for plasma norepinephrine by the method employed average 
342 i: 30 pgiml(l1). All patients experienced a reduction in 
norepinephrine levels, except Patient 1, whose norepineph- 
rine levels remained unchanged. This patient received the 
lowest dose of metyrosine and was also the only one with 
normal baseline norepinephrine values. 
Figure 1. Relation between response to metyrosine and baseline 
plasma norepinephrine (NE) concentration in nine patients with 
congestive heart failure. 
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Table 3. Neurohumoral Responses to Metyrosine Administration in Nine Patients With Congestive Heart Failure 
Patient 
No. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
Mean 
? SD 
P 
C 
263 
511 
2.548 
418 
448 
674 
492 
2,288 
567 
919.4 
810.6 
Norepinephrine 
24 h 48 h 
203 360 
222 281 
806 708 
308 248 
265 339 
124 286 
670 297 
538 339 
360 161 
388.4 335.4 
218.7 143.1 
NS <0.05 
72 h 
158 
195 
623 
336 
- 
300 
1,018 
?OO 
404.3 
289.4 
NS 
Epinephrine 
C 
27 
117 
708 
10 
53 
57 
88 
320 
186 
174.0 
209.3 
24 h 
11 
94 
391 
46 
184 
62 
99 
539 
162 
176.4 
166.0 
NS 
48h 
-82 
162 
474 
210 
241 
181 
156 
526 
133 
240.6 
145.5 
NS 
72 h 
7 
64 
134 
60 
119 
482 
133 
142.7 
145.1 
NS 
C = control: h = hours after metyrosine administration. 
The magnitude of the decrease in norepinephrine levels 
averaged 42.0 + 34.3% (p < 0.01) and 45.1 + 34.1% (p < 
0.01) at 24 and 48 h, respectively, after metyrosine adminis- 
tration. In the seven patients whose norepinephrine levels 
were obtained at 72 h (that is, 24 h after cessation of 
metyrosine administration), norepinephrine levels were no 
longer significantly reduced from control values, suggesting 
a true drug effect rather than a spontaneous decrease in 
norepinephrine levels during metyrosine administration. 
Baseline norepinephrine values failed to correlate with the 
change in norepinephrine levels produced by metyrosine 
(Fig. 1). Furthermore, there was no significant correlation 
between baseline norepinephrine values and baseline plasma 
renin activity (r = 0.39, p = NS), which was also elevated at 
6.3 + 6.5 ngiml per h. 
Hemodynamic responses after administration of metyrosine 
(Table 4). Satisfactory pulmonary artery pressure tracings 
could not be obtained at baseline study in two patients 
(Patients 3 and 6). Both patients were included in the study, 
however, because one (Patient 3) had a very high right atria1 
pressure and both had low cardiac output and stroke volume. 
At baseline study, pulmonary wedge pressure for the group 
averaged 27.4 2 8.5 mm Hg, and cardiac output was 3.69 f 
1.03 litersimin, indicating severe hemodynamic compromise. 
Despite these severe hemodynamic abnormalities at baseline 
study, no significant changes in any hemodynamic variable 
were observed after either 24 or 48 h of metyrosine adminis- 
tration. Furthermore, there were no significant correlations 
between norepinephrine or epinephrine plasma concentra- 
tions and any hemodynamic variable at baseline study or 
during metyrosine administration (Table 5). 
Discussion 
Role of circulating norepinephrine in heart failure. Al- 
though it is generally accepted that increased levels of 
Table 4. Hemodynamic Responses to Metyrosine Administration in Nine Patients With Congestive Heart Failure 
Heart Rate Right Atria1 Mean Arterial Pulmonary Wedge Cardiac Output Stroke Volume Systemic Vascular 
Patient 
(beatslmin) Pressure (mm Hg) Pressure (mm Hg) Pressure (mm Hg) (litershin) (mllbeat) Resistance (units) 
No. C 24 h 48 h C 24 h 48 h C 24 h 48 h C 24 h 48 h C 24 h 48 h C 24 h 48 h C 24 h 48 h 
1 62 66 69 11 14 12 88 90 90 42 43 43 3.06 2.69 2.66 49 41 39 25 28 29 
2 81 90 100 II R - 73 65 72 25 21 18 2.95 4.34 3.12 36 48 31 21 13 - 
3 108 100 99 22 21 18 74 66 73 - - - 2.38 2.43 2.91 22 24 29 22 19 19 
4 ‘7X 84 81 9 9 IO 88 81 81 22 23 18 5.42 4.70 4.92 69 56 61 15 I5 14 
5 90 93 90 11 8 15 87 90 99 26 20 34 5.24 5.06 5.11 58 54 57 15 16 16 
6 III 99 108 5 9 5 87 93 87 - - - 3.24 4.52 3.01 29 46 28 25 19 27 
7 80 84 84 8 8 4 118 loo 109 25 II IO 3.29 4.05 3.54 41 48 42 33 23 30 
8 98 86 81 15 14 21 101 88 85 37 28 37 3.09 4.20 3.49 32 49 43 28 18 18 
9 ‘77 66 63 6 8 4 111 103 104 15 - 7 4.54 3.63 4.88 59 55 77 23 26 20 
Mean 81.2 85.3 86.1 10.9 11.0 II.1 91.9 86.2 88.9 27.4 24.3 23.9 3.69 3.96 3.74 44.0 46.8 45.2 23.0 19.6 21.9 
SD 15.0 11.7 13.9 4.8 4.2 6.1 14.5 12.6 12.3 8.5 9.8 13.0 1.03 0.84 0.91 15.X 9.5 16.5 6.0 3.9 5.6 
p - NS NS - NS NS - NS NS - NS NS - NS NS - NS NS - NS NS 
Abbreviations as m Table 3. 
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Table 5. Relation Between Neurohumoral Factors and 
Hemodynamics in Nine Patients With Congestive Heart Failure 
Given Metyrosine 
Independent 
Variable 
Dependent 
Variable r P 
Con1rol 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma E 
Plasma E 
Plasma E 
Plasma E 
Plasma E 
48 hours after metyrosine 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma NE 
Plasma E 
Plasma E 
Plasma E 
Plasma E 
Plasma E 
HR 
hlAP 
PWP 
CO 
SVR 
HR 
MAP 
co 
SVR 
HR 
MAP 
PWP 
co 
SVR 
HR 
MAP 
PWP 
co 
SVR 
0.65 NS 
0.19 NS 
0.34 NS 
0.52 NS 
0.19 NS 
0.55 NS 
0.25 NS 
0.08 NS 
0.53 NS 
0.11 NS 
0.40 NS 
0.48 NS 
0.84 NS* 
0.47 NS 
0.06 NS 
0.26 NS 
0.41 NS 
0.35 NS 
0.12 NS 
0.44 NS 
*p < 0.02; >O.Ol is not significant because of Bonferroni correction 
requiring p < 0.0015. CO = cardiac output; E = epinephrine; HR = heart rate; 
MAP = mean systemic arterial pressure: NE = norepinephrine: NS = not 
significant; PWP = pulmonary wedge pressure; SVR = systemic vascular 
resistance. 
circulating norepinephrine in patients with heart failure are 
indicative of augmented sympathetic nervous activity, the 
origin and significance of this heightened adrenergic drive 
are unclear (3-5,12-14). Depletion of myocardial norepi- 
nephrine stores together with normal circulating epinephrine 
(of adrenal medullary origin) suggests that the circulating 
norepinephrine in patients with heart failure derives from 
peripheral sympathetic nerves (12,13). Given the well known 
pharmacologic effects of circulating catecholamines on the 
cardiovascular system, the widespread use of exogenous 
sympathomimetic agents to improve hemodynamics in states 
of circulatory insufficiency and the increase in plasma cate- 
cholamine levels in response to stress. it has been logical to 
conclude that an increase in circulating norepinephrine lev- 
els represents a beneficial and necessary compensatory 
response in patients with heart failure (4,13,14). In contrast, 
the harmful effects of vasoconstriction on cardiovascular 
performance and observations that elevated plasma norepi- 
nephrine levels correlate directly with worse symptoms and 
a lower survival rate in patients with congestive heart failure 
suggest a detrimental role of excess catecholamines (3,13, 
15). The cardiotoxic effects of catecholamines are well 
known (15,16). Finally, adding to the difficulty in interpreting 
the role of catecholamines in patients with heart failure are 
the findings that cardiac beta-receptor density and sensitivity 
are reduced in such patients and that these can be restored in 
association with clinical improvement during long-term ad- 
ministration of beta adrenergic blockers in some patients 
with chronic congestive heart failure (1,2,17,18). 
Attempts to distinguish the role of circulating norepi- 
nephrine as a significant pathophysiologic determinant or 
mere marker of advanced coronary heart disease have relied 
on nonspecific pharmacologic interventions. The widespread 
use of sympathomimetic agents to treat acute heart failure 
supports the notion that circulating catecholamines provide 
important circulatory support, yet prolonged use of these 
agents has been associated with undesirable effects including 
arrhythmias and death (19.20). Furthermore, these agents 
may affect multiple dopaminergic and adrenergic receptors, 
and may not truly mimic the effects of endogenous catechol- 
amines. In fact, exogenously administered norepinephrine 
produces blunted responses in patients with heart failure, 
and very large doses are required to produce even these 
effects (15). 
Interventions intended to reduce adrenergic drive have 
also yielded inconsistent results. Administration of bro- 
mocriptine, which reduces circulating norepinephrine by 
inhibiting its release, has been associated with hemodynamic 
improvement in patients with chronic heart failure, but this 
agent may have direct vasodilating activity (21). In similar 
patients from the same laboratory (15), guanabenz acetate 
also reduced norepinephrine levels but did not aEect hemo- 
dynamics. Thus, the effect of circulating norepinephrine on 
hemodynamics in patients with chronic congestive heart 
failure has not yet been clearly defined. 
Significance of the present results. In this study, inhibition 
of norepinephrine synthesis by metyrosine resulted in a 
marked reduction in plasma norepinephrine levels, which 
decreased almost threefold to within the normal range. 
Despite this striking neurohumoral alteration, systemic he- 
modynamics were unchanged. Because the only known 
action of metyrosine is its inhibition of synthesis of norepi- 
nephrine in peripheral nerves (9, lo), it is unlikely that other 
actions of this agent could have offset any effects produced 
by removal of norepinephrine from the circulation. Thus, 
our results represent the first demonstration of the effects of 
“pure” norepinephrine inhibition in patients with heart 
failure. Not only did the reduction in plasma norepinephrine 
fail to alter hemodynamics, but baseline plasma norepineph- 
rine levels were not related to any baseline hemodynamic 
variable or to plasma renin activity. Furthermore, the 
changes in norepinephrine levels and hemodynamic re- 
sponses during metyrosine administration were also unre- 
lated. 
These results suggest that absolute levels or changes in 
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levels of circulating norepinephrine do not contribute signif- 
icantly to the hemodynamic abnormalities observed in pa- 
Gents with moderate to severe chronic heart failure. Our 
observations are surprising in that the patients studied had 
acutely decompensated moderate to severe chronic left 
ventricular failure with marked hemodynamic abnormalities. 
In such patients, exogenous sympathomimetic agents and 
vasodilator drugs are commonly administered, alone or 
together. with resulting hemodynamic improvement. The 
present results indicate that such improvement is not medi- 
ated through circulating norepinephrine. Thus, it appears 
that the high levels of circulating norepinephrine in patients 
with moderate to severe congestive heart failure represent a 
mere marker of advanced coronary heart disease without 
contributing significantly to the underlying pathophysiology 
at that stage of the process. Similar observations have been 
made in conscious dogs (22). 
Limitations of the study. The present results can not be 
extrapolated to mean that norepinephrine plays no important 
role in the pathophysiology of heart failure. Our observa- 
tions were limited to patients with advanced coronary heart 
disease who were studied at rest and only over a 48 h period 
of observation. It is possible that circulating norepinephrine 
plays an important role during periods of stress such as 
exercise. Furthermore, it is now established (17.18) that 
beta-receptor density and responsiveness are reduced in 
chronic heart failure associated with high levels of circulat- 
ing catecholamines and that antiadrenergic agents can re- 
store beta-receptor levels and responsiveness over time. 
Thus, more prolonged administration of metyrosine might 
have resulted in significant hemodynamic changes in our 
study patients. 
The present results might also reject inadequate reduc- 
formance of the failing heart with its reduced beta,-receptor 
integrity (27). 
The discrepancy between the present results and previous 
observations that alpha-receptor antagonists produce imme- 
diate vasodilation and hemodynamic improvement in pa- 
Gents with heart failure may relate to some of the mecha- 
nisms described herein (28,29). Thus, any amount of 
circulating norepinephrine may be regarded as excessive 
relative to the amounts required for activity at the alpha- 
receptor level. Furthermore. these receptors may be re- 
spending to other vasoconstrictor influences in addition to 
norepinephrine, or the alpha-receptor blocking agents may 
possess direct vasodilating activity. 
Conclusions. Our results suggest that the high levels of 
plasma norepinephrine observed in patients with chronic 
congestive heart failure do not contribute significantly to the 
hemodynamic abnormalities observed at rest in these pa- 
tients with advanced heart failure. Norepinephrine may still 
be important in initiating the vicious cycle of heart failure 
because the adrenergic nervous system is activated very 
early in patients after acute myocardial infarction, and the 
magnitude of this change relates to the extent of myocardial 
damage as well as to survival (30). Once the process of heart 
failure becomes established, other mechanisms may become 
more influential in the maintenance or progression of dis- 
ease, and circulating norepinephrine may become more of a 
marker at that stage. Clarification of the ultimate role of 
circulating catecholamines in the pathophysiology of heart 
failure requires further study. In the meantime, our results 
support the concept that manipulation of the adrenergic 
nervous system as a therapeutic intervention can be safely 
investigated. 
tion of plasma norepinephrine. Although plasma norepi- 
nephrine levels decreased almost threefold to within the 
normal range, even this reduced level may represent an 
excess, given the tiny amounts needed at the neuroeffector 
junction. Plasma catecholamine levels are thought to repre- 
sent excess amounts entering the circulation after local 
metabolism and reuptake (23). Nevertheless, the degree of 
reduction in plasma norepinephrine in the present study is 
comparable with that observed in states of known catechol- 
amine dependency, such as pheochromocytoma. where both 
blood uressure and heart failure have been controlled by 
metyrdsine administration (9.10.24). 
Another possible explanation for the present results is 
that other neurohumoral factors were playing a more influ- 
ential role. Plasma renin activity w& increased in our 
patients. In addition, circulating epinephrine was not re- 
duced by metyrosine, and it has been suggested (25) that 
epinephrine is a more important determinant of blood pres- 
sure than is norepinephrine. Epinephrine may also affect 
cardiac performance through beta,-receptors (26). These 
receptors may assume greater importance in regulating per- 
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